Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kailera Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kailera Therapeutics's regulatory disclosures and financial reporting.
Kailera Therapeutics, Inc. director, CEO and President Ronald C. Renaud Jr. reports holdings of multiple stock options to buy Common Stock. These options cover blocks of underlying shares at exercise prices of $7.2400 and $5.2500 per share with expiration dates in 2034 and 2035.
Footnotes state that certain options are already fully vested, while others vest over time, typically with 33% or 25% vesting on an initial date and the remainder in substantially equal monthly installments, subject to his continued service.
Kailera Therapeutics director Frank Clyburn reports holding a stock option covering 170,194 shares of common stock at an exercise price of $7.24 per share. The option expires on November 5, 2035 and vests 25% on October 31, 2026, then in 36 substantially equal monthly installments.
Kailera Therapeutics, Inc. disclosed the stock option holdings of its Chief Legal Officer, Scott Akamine. He holds options to buy 193,999 shares of common stock at an exercise price of $7.24 per share, expiring on November 5, 2035.
He also holds options tied to 143,673 and 213,890 underlying shares at an exercise price of $5.25 per share, both expiring on December 9, 2034. These options vest 25% on specified initial vesting dates, then in 36 monthly installments, subject to his continued service with the company.